flow trial semaglutide nejm Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential FLOWing with the SemagluTIDE —
Description
However, our armamentarium has another option with weight loss medications like Wegovy and Zepbound, also known as GLP-1 receptor agonists
These technical safety aspects, as well as the ability of the patient to communicate symptoms, must be carefully considered for future studies
Pantoprazole can reduce the activation of clopidogrel, leading to decreased efficacy of the antiplatelet drug
Most of the "GLP-1 flu" feelings come from dehydration
People sometimes wonder whether they should adjust their dose after a suspected potency loss
